UnitedHealth agrees to sell South American business to private equity firm Patria for $1 billion, sources say

UnitedHealth has agreed to sell its remaining South American business, Banmedica, to Brazilian private equity firm Patria Investments for $1 billion, completing a multi-year exit from the region; Banmedica serves 1.7 million members and operates seven hospitals and 47 medical centers in Colombia and Chile. The move, which follows earlier Brazil and Peru divestments and a prior $1.2 billion loss tied to Banmedica (part of an $8.3 billion South America charge), is intended to remove a distraction for returning CEO Stephen Hemsley as the company pursues a turnaround after raising its annual profit forecast and targeting a return to growth in 2026. The sale is expected to be announced imminently and represents a modest but strategic portfolio simplification rather than a material capital event for UnitedHealth.

Analysis

Market structure: The Banmedica sale crystallizes a shift — private equity (Patria) and regional operators are winners; UnitedHealth (UNH) and US-focused payors gain concentration and management bandwidth to hit 2026 growth targets. The deal is economically small ($1bn proceeds vs. prior $8.3bn charge) but materially reduces operational complexity, improving UNH’s cash redeployment optionality and likely tightening its credit spreads by 10–30bps over 6–12 months. Impact on FX and commodities is negligible; options IV on UNH should compress after official announcement and confirmation of proceeds use.

Risk assessment: Tail risks include regulatory interventions in Chile/Colombia or undisclosed contingent liabilities that could create a $0.5–1.0bn cash drag, and renewed US federal scrutiny that could delay domestic margin recovery. Immediate (days) risk is limited to repricing on the press release; short-term (weeks–months) hinges on how proceeds are allocated (buybacks vs. capex); long-term (2026–2027) execution risk centers on Medicare policy and medical-cost inflation. Hidden dependency: prior $8.3bn non‑cash loss masks real cash benefits—monitor tax and repatriation mechanics for clarity on free-cash-flow impact.

Trade implications: Tactical idea — overweight UNH (1.5–3% portfolio) funded by trimming emerging-market healthcare/EM equity exposure by 1–2%, targeting 12–18% upside into 12–18 months as execution stabilizes. Use options to express view: buy 9–15 month UNH call spreads (delta 0.3–0.5) or buy Jan-2026 LEAPS and sell near-term calls to monetize IV decay; add a 3–6 month protective put around earnings if entering before guidance updates. Consider a relative-value pair: long UNH, short Centene (CNC) sized 1:0.5 (expect UNH re-rating if domestic focus yields margin improvement).

Contrarian angles: Consensus treats the sale as housekeeping; that understates potential FCF uplift — if even $1bn is returned to buybacks, EPS could be 1–2% accretive in 12 months, suggesting current sentiment may be underpricing re-rating. Conversely, private-equity ownership could accelerate regional consolidation, eventually increasing cross-border competition when UNH re-enters or partners, a risk to assume when modeling 2027 growth. Historical parallels: payer exits from EM often precede multi-year domestic re-rating (look at prior Aetna/Anthem divestitures), but watch for execution slippage and unforeseen liabilities that flip the thesis.

Key Decisions for Investors

• Establish a 1.5–3.0% portfolio long position in UNH within 2–6 weeks post-official announcement; target 12–18% upside over 12–18 months, take profits at +18% or trim if UNH repurchases >$1bn announced.
• Implement an options collar if entering pre-earnings: buy 9–15 month UNH call spread (delta ~0.35–0.5) financed by selling near-term (30–60 day) calls; adjust strikes to cap cost at <50bps of position size.
• Execute a pair trade: long UNH (1.0%) / short CNC (0.5%) for a 6–12 month horizon, expecting UNH to outgrow Centene on improved operational focus—stop-loss 6% on relative performance.